-
Mashup Score: 4Networks that stop the flow: A fresh look at fibrin and neutrophil extracellular traps - 14 hour(s) ago
Neutrophil extracellular traps (NETs) are DNA and histone-based networks enriched with granule-derived proteins cast out by neutrophils in response to various inflammatory stimuli. Another molecular network, fibrin is the primary protein scaffold that holds both physiological blood clots and pathological thrombi together. There is mounting evidence that NETs and fibrin form a composite network within thrombi: in the past 10 years, a variety of molecular pathways have been revealed that help elucidate the nature of the NET-fibrin interaction.
Source: www.thrombosisresearch.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9Is there a role for the laboratory monitoring in the management of specific antidotes of direct oral anticoagulants? - 26 day(s) ago
Given the growing number of patients receiving direct oral anticoagulant (DOAC), patients requiring rapid neutralization is also increasing in case of major bleedings or urgent surgery/procedures. Idarucizumab is commercialized as a specific antidote to dabigatran while andexanet alfa has gained the Food and Drug Administration and the European Medicines Agency approval as an oral anti-factor Xa inhibitors antidote. Other antidotes or hemostatic agents are still under preclinical or clinical development, the most advanced being ciraparantag.
Source: www.thrombosisresearch.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 6A comparative in vitro study of the anticoagulant effect of branded versus generic rivaroxaban - 2 month(s) ago
Several generic formulations of rivaroxaban were recently marketed to be used interchangeably with their branded equivalent. However, there have been no previously published studies that directly compared the in vitro anticoagulant effect of branded vs. generic rivaroxaban. The aim of this in vitro study was to compare the effects of three raw rivaroxaban materials, obtained from the branded (Xarelto®) and two generic (Rivarolto® and Rivaroxaban Sandoz®) rivaroxaban formulations on an array of coagulation assays.
Source: www.thrombosisresearch.comCategories: General Medicine News, Onc News and JournalsTweet
Reference: https://t.co/lMSH443wIQ